Arvin Yang - Nov 30, 2021 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)

Role
Chief Medical Officer
Signature
Brian DeSchuytner, as Attorney-in-Fact
Stock symbol
MRSN
Transactions as of
Nov 30, 2021
Transactions value $
-$37,639
Form type
4
Date filed
12/2/2021, 04:00 PM
Next filing
Jan 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRSN Common Stock Options Exercise +18.5K 18.5K Nov 30, 2021 Direct F1
transaction MRSN Common Stock Sale -$37.6K -5.53K -29.88% $6.81* 13K Dec 1, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRSN Restricted Stock Units Options Exercise $0 -18.5K -50% $0.00 18.5K Nov 30, 2021 Common Stock 18.5K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.
F2 Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II. These sales were mandated by the Issuer's election under its equity incentive plans to require the reporting person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the reporting person.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $6.68 to $7.00, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any security holder of Mersana Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4 50% of the total number of RSUs vested on November 30, 2021, and the remainder of the total number of RSUs shall vest on November 30, 2022.